Tri-Moxi intraocular injection recalled for glass particle contamination
Imprimis NJOF is recalling Tri-Moxi intraocular injection due to glass-like particles found in certain lots. These particles could pose a risk to eye safety if injected.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of a high-risk product (intraocular injection) contaminated with glass particles. Although no illnesses or injuries have been reported, the direct injection of particulate matter into the eye presents a significant risk-of-harm scenario, meeting the rubric criterion for High severity.
Plain-English summary
Imprimis NJOF, LLC is recalling Tri-Moxi (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6mg/0.6mL) Single-Use Intraocular Injection due to the presence of glass-like particulate matter in the product.
The affected lots are 25JAN033A and 25JAN033B, which expire on 02/12/2026. A total of 314 boxes containing 6,280 pre-filled syringes were distributed nationwide across the United States.
Because this product is designed to be injected directly into the eye, the presence of glass particles presents a potential risk to eye tissue and vision. Healthcare providers and patients who have the affected lots should contact their healthcare provider or the manufacturer for guidance regarding replacement or next steps.
The recalled product
- Product
- Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.
- Manufacturer
- Imprimis NJOF, LLC
- Hazard
- particulate-matter
- glass-particles
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot: 25JAN033A
- 25JAN033B
- Expires: 02/12/2026.
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- ModerateGas-X Simethicone 125 mg softgels recall for incomplete labeling
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27